Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Total Current Liabilities: 2014-2025

Historic Total Current Liabilities for RedHill Biopharma (RDHL) over the last 1 years, with Jun 2025 value amounting to $22.3 million.

  • RedHill Biopharma's Total Current Liabilities rose 4.96% to $22.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $22.3 million, marking a year-over-year increase of 4.96%. This contributed to the annual value of $22.2 million for FY2024, which is 11.21% up from last year.
  • Latest data reveals that RedHill Biopharma reported Total Current Liabilities of $22.3 million as of Q2 2025, which was up 0.29% from $22.2 million recorded in Q4 2024.
  • Over the past 5 years, RedHill Biopharma's Total Current Liabilities peaked at $197.5 million during Q4 2022, and registered a low of $20.0 million during Q4 2023.
  • Moreover, its 3-year median value for Total Current Liabilities was $22.2 million (2024), whereas its average is $22.8 million.
  • As far as peak fluctuations go, RedHill Biopharma's Total Current Liabilities spiked by 142.36% in 2022, and later crashed by 89.88% in 2023.
  • Quarterly analysis of 5 years shows RedHill Biopharma's Total Current Liabilities stood at $81.5 million in 2021, then skyrocketed by 142.36% to $197.5 million in 2022, then tumbled by 89.88% to $20.0 million in 2023, then climbed by 11.21% to $22.2 million in 2024, then climbed by 4.96% to $22.3 million in 2025.
  • Its Total Current Liabilities stands at $22.3 million for Q2 2025, versus $22.2 million for Q4 2024 and $21.2 million for Q2 2024.